anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Keratinous fibres, particularly live human hair, are deformed by applying to them, either before and/or after constraining them into the desired configuration, an aqueous solution adjusted to a pH of 9-10 comprising at least one water soluble alkali metal sulphite or metabisulphite and sodium and/or potassium borohydride in the proportion of one mole of sulphite or metabisulphite to 1-20 moles of borohydride, the total quantity of reducing agents employed being such that the concentration of active hydrogen theoretically available is not more than 2 grams per 100 c.c. of p  the aqueous reducing solution, leaving the solution in contact with the fibres for at least 15 minutes and thereafter rinsing, fixing and drying. Specified alkali metal sulphites and meta bisulphites are sodium, potassium and lithium sulphites and sodium and potassium metabisulphites.  The pH of the solutions may be controlled by the use of reactants, e.g. boric acid alone or mixed with calcium chloride, tartaric acid, citric acid, lactic acid, dihydrogen ortho-sodium phosphate, glycine, sarcosine, and taurine, capable of forming buffered systems under the conditions employed.  These reactants may be added in two fractions, the first being incorporated into the treating solution at the commencement of the fibre treatment and the second being applied to the fibres during the course of treatment, e.g. by spraying. The solution may also contain water miscible penetrating agents, e.g. lower fatty alcohols, such as ethanol and iso propanol, glycols and ethers or ether-esters of glycols, and cyclic ethers, e.g. dioxane and dioxolane.  The pentrating agent may also be a binder or carrier, e.g. a polycondensate of ethylene oxide, having uniformly embedded therein the alkali metal sulphites or metabisulphites, the borohydrides and the acid buffing reactant prepared according to Specification 828,208 which is subsequently dissolved in water to form the fibre treating solution.  The solution may also contain water miscible swelling agents, e.g. urea, thiourea, formamide, acetamide and the amides of other carboxylic acids and hydroxy-carboxylic acids, and organic heterocyclic nitrogenous bases, e.g. N-lactarylpiperidine.  After rinsing the fibres may be fixed with dilute hydrogen peroxide or an aqueous sodium bromate solution and dried or they may be rinsed with a dilute solution of a weak organic acid, e.g. lactic or citric acids, and left for reoxidation to take place under the action of the ambient air.  The process may be used for smoothing kinky hair or permanently waving straight hair.  Specification 835,247 also is referred to.
A method and a system for medical image interpretation are provided. A medical image is provided to a convolutional neural network model. The convolutional neural network model includes a feature extraction part, a first classifier, and N second classifiers. N feature maps are generated by using the last layer of the feature extraction part of the convolutional neural network model. N symptom interpretation results of N symptoms of a disease are obtained based on the N feature maps through the N second classifiers. A disease interpretation result of the disease is obtained based on the N feature maps through the first classifier.
Each patient received subcutaneous low-molecular-weight heparin in adjusted doses for 10 to 14 days, followed by oral anticoagulants (warfarin or dabigatran or rivaroxaban, if warfarin was used, PT-INR was maintained between 2.0 and 3.0) for 6 months or more. The use of endovascular treatment (local thrombectomy/thrombolysis) was reserved for patients who are still progressing with adequate anticoagulant therapy.
Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
SLGT2 therapy is safety used in heart failure (HF) patients with depressed left ventricle ejection fraction (LVEF) and diabetes mellitus (DM). Indeed, in these patients SGLT2 therapy reduces hospital admission for heart failure and mortality rate. To date, these patients experience higher rate of ventricular arrhythmias (VA), that are a leading cause of cardiac arrest and mortality. However, as indicated by international guidelines, these patients can be treated by implantable cardioverter defibrillator (ICD) and CRTd as primary and/or secondary prevention therapy. Consequently, the effectiveness of ICD and CRTd is to treat sustained VA, and to reduce cardiac arrest events and mortality. Indeed, ICDs/CRTds' anti-tachycardia pacing and shocks can interrupt VA, and this might prevent a cardiac arrest event. This therapeutic effect can positively impact on acute and long term patients' survival. On other hand, authors showed that, continuous VA events and ICDs' interventions are causes of reduced patients' life expectancy in HF patients. This worse prognosis is particularly evidenced in failing heart patients with DM as compared to patients without DM. In this setting, the catheter ablation (CA) treatment has been used to reduce the ventricular arrhythmias and the ICDs/CRTds' interventions, and to prevent mortality events in these patients. On other hand, still a higher percentage of patients result as non responders to an ablative approach with higher acute and long term mortality rate. Among these non responders patients to an ablative approach, DM is a negative prognostic factor. Therefore, in the present study in a population of HF patients (DM vs. non DM patients) with VA authors will investigate the effects of CA on mortality rate at 12 months of follow up. In addition, authors would like to demonstrate the ameliorative effects of new hypoglycemic drugs in addition to CA in patients with DM. However, after CA the patients with DM will be randomly assigned to SGLT2 therapy vs. placebo. Indeed, study hypothesis will be that, a) DM vs. non DM might have higher mortality rate after CA; b) patients with DM treated by CA plus SLGT2 therapy vs. patients with DM treated by CA plus placebo might experience a lower rate of mortality at 1 year of follow-up. Therefore, study aim will be to demonstrate a reduction of VA, ICDs/CRTds' interventions, and mortality in patients with DM treated by CA plus SLGT2 therapy vs. patients with DM treated by CA plus placebo at 12 months of follow-up.
PROBLEM TO BE SOLVED: To enable the use of the subject compound, available from a high- molecular chitin such as that of a crab, readily synthesized and having a sufficient water solubility and excellent hairdressing effects as a hairdressing agent. SOLUTION: At least one of this O-hydroxyalkylchitin having at least one monomer unit represented by the formula [R is a 2-20C alkylene; (n) is >=1] (e.g. hydroxypropylchitin) is used in a hairdressing agent. The O- hydroxyalkylchitin is obtained by reacting chitin with an alkalifying agent (e.g. an aqueous solution of sodium hydroxide at 1-43% concentration) under cooling to -78 deg.C at least once, then dissolving the reaction product at ambient temperature therein and then reacting the resultant solution with an excessive amount of at least one alkylene oxide having a 2-20C alkyl group (e.g. propylene oxide) at 30-100 deg.C, isolating and purifying the prepared reaction product according to a conventional method.
First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
BACKGROUND: The aim of this multicentre prospective audit was to describe the current practice in the management of mastitis and breast abscesses in the UK and Ireland, with a specific focus on rates of surgical intervention.
METHODS: This audit was conducted in two phases from August 2020 to August 2021; a phase 1 practice survey and a phase 2 prospective audit. Primary outcome measurements for phase 2 included patient management pathway characteristics and treatment type (medical/radiological/surgical).
RESULTS: A total of 69 hospitals participated in phase 2 (1312 patients). The key findings were a high overall rate of incision and drainage (21.0 per cent) and a lower than anticipated proportion of ultrasound-guided aspiration of breast abscesses (61.0 per cent). Significant variations were observed regarding the rate of incision and drainage (range 0-100 per cent; P < 0.001) and the rate of needle aspiration (range 12.5-100 per cent; P < 0.001) between individual units. Overall, 22.5 per cent of patients were admitted for inpatient treatment, out of whom which 72.9 per cent were commenced on intravenous antibiotics. The odds of undergoing incision and drainage for a breast abscess or being admitted for inpatient treatment were significantly higher if patients presented at the weekend compared with a weekday (P ≤ 0.023). Breast specialists reviewed 40.9 per cent of all patients directly, despite the majority of patients (74.2 per cent) presenting within working hours on weekdays.
CONCLUSIONS: Variation in practice exists in the management of mastitis and breast abscesses, with high rates of incision and drainage in certain regions of the UK. There is an urgent need for a national best-practice toolbox to minimize practice variation and standardize patient care.
INTRODUCTION: Anorexia nervosa (AN) in older adult women is primarily described through reviews or case reports focusing on psychiatric traits, with no comprehensive studies evaluating their complete nutritional and hormonal profiles. This study aimed to describe a group of women with anorexia nervosa aged above 35 years old (AN35), and compare them with young women with anorexia nervosa (ANY) and normal-weight control participants.
METHOD: Anthropometric, metabolic, nutritional, and psychiatric parameters were collected and compared among three groups of women: 50 AN35, 37 ANY, and 38 controls.
RESULTS: AN35 exhibited a mean disease duration of 271 ± 19 months, with 94% chronic forms and 58% restrictive types. Despite having similar BMI as ANY, AN35 displayed more altered parameters, including higher liver enzymes (p = 0.007), free T3 (p = 0.0046) and leptin (p < 0.0001); and lower albumin (p = 0.0029), and white cells (p < 0.0001). AN35 showed significant heterogeneity in hormonal adaptation, such as free T3. Half of the patients aged above 51 years revealed high gonadotropin levels despite being undernourished. Additionally, AN35 groups presented with 50% of bones fractures, decreased T-scores under -2.5 (p < 0.0001 for femoral), and altered micro architectural HRPQT parameters compared to ANY.
CONCLUSION: Anorexia nervosa in older adult women is predominantly chronic. Nutritional parameters changes with age suggests a significant heterogeneity and possible adaptation of energy balance and bodyweight set point for others. Complications may be severe, altering the quality of life, and sometimes potentially lethal. These findings highlight the potential adaptation of energy balance with age, and should assist clinicians in clinical practice.
Participants will take Placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) will be taken by participants in placebo groups for 6 weeks. Alongside supplementation, participants will engage in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program, 3 days/week, for 6 weeks.
BACKGROUND: Ischemia-reperfusion injury (IRI) is an unavoidable consequence post-kidney transplantation, which inevitably leads to kidney damage. Numerous studies have demonstrated that mitophagy is implicated in human cancers. However, the function of mitophagy in kidney transplantation remains poorly understood. This study aims to develop mitophagy-related gene (MRGs) signatures to predict delayed graft function (DGF) and renal allograft loss post-kidney transplantation.
METHODS: Differentially expressed genes (DEGs) were identified and intersected with the MRGs to obtain mitophagy-related DEGs (MRDEGs). Functional enrichment analyses were conducted. Subsequently, random forest and SVM-RFE machine learning were employed to identify hub genes. The DGF diagnostic prediction signature was constructed using LASSO regression analysis. The renal allograft prognostic prediction signature was developed through univariate Cox and LASSO regression analysis. In addition, ROC curves, immunological characterization, correlation analysis, and survival analysis were performed.
RESULTS: Nineteen MRDEGs were obtained by intersecting 61 DEGs with 4897 MRGs. Seven hub genes were then identified through machine learning. Subsequently, a five-gene DGF diagnostic prediction signature was established, with ROC curves indicating its high diagnostic value for DGF. Immune infiltration analysis revealed that many immune cells were more abundant in the DGF group compared to the Immediate Graft Function (IGF) group. A two-gene prognostic signature was developed, which accurately predicted renal allografts prognosis.
CONCLUSIONS: The mitophagy-related gene signatures demonstrated high predictive accuracy for DGF and renal allograft loss. Our study may provide new perspectives on prognosis and treatment strategies post-kidney transplantation.
Genetic variants of gene SCN5A encoding the alpha-subunit of cardiac voltage-gated sodium channel Nav1.5 are associated with various diseases, including long QT syndrome (LQT3), Brugada syndrome (BrS1), and progressive cardiac conduction disease (PCCD). In the last decades, the great progress in understanding molecular and biophysical mechanisms of these diseases has been achieved. The LQT3 syndrome is associated with gain-of-function of sodium channels Nav1.5 due to impaired inactivation, enhanced activation, accelerated recovery from inactivation or the late current appearance. In contrast, BrS1 and PCCD are associated with the Nav1.5 loss-of-function, which in electrophysiological experiments can be manifested as reduced current density, enhanced fast or slow inactivation, impaired activation, or decelerated recovery from inactivation. Genetic variants associated with congenital arrhythmias can also disturb interactions of the Nav1.5 channel with different proteins or drugs and cause unexpected reactions to drug administration. Furthermore, mutations can affect post-translational modifications of the channels and their sensitivity to pH and temperature. Here we briefly review the current knowledge on biophysical mechanisms of LQT3, BrS1 and PCCD. We focus on limitations of studies that use heterologous expression systems and induced pluripotent stem cells (iPSC) derived cardiac myocytes and summarize our understanding of genotype-phenotype relations of SCN5A mutations.
A brain tumor types distinguish system includes an image outputting device and a server computing device. The image outputting device outputs at least three brain images captured from the position of a brain tumor. The server computing device pre-stores a plurality of distinguish pathways corresponding to different types of brain tumors. The server computing device includes an image receiving module, an image pre-processing module, a data comparison module and a distinguish module. The image receiving module receives the brain images. The image pre-processing module pre-processes the brain images to obtain corresponding processed images thereof. The data comparison module compares the brain images and the processed images with the distinguish pathways to obtain at least three comparison results. The distinguish module statistically analyzes the comparison results to obtain a distinguish result.
PURPOSE: The primary aim of this pilot study was to determine the preliminary effectiveness of an online self-compassion intervention for improving self-compassion and quality of life in adults who stutter. A secondary aim was to determine intervention acceptability and participant satisfaction.
METHOD: Participants included adults who stutter who completed an online self-compassion module once a week for six consecutive weeks. Pre- and post-intervention measures included the Self-Compassion Scale-Trait and the Overall Assessment of the Speaker's Experience of Stuttering. Participants also completed acceptability questionnaires weekly and post-intervention via quantitative and qualitative reports.
RESULT: Ten participants completed all six intervention modules, as well as pre- and post-intervention measures. Participants reported increased self-compassion and improved quality of life at post-intervention, as well as high intervention acceptability with regard to delivery format, content, duration, and relevance to stuttering and daily life. Individual variation was also observed across acceptability domains.
CONCLUSION: The present study provides pilot data supporting the use of online modules to increase self-compassion and decrease the negative impact of stuttering on the quality of life among adults who stutter. Future studies should employ larger sample sizes, compare outcomes to a control group, and determine if gains are maintained over time.
Systems, methods, and instrumentalities are disclosed for automatic compilation, annotation, and dissemination of surgical data to systems to anticipate related automated operations. Surgical procedure data may be selectively sent to surgical systems, for example, to perform autonomous tasks (e.g., without being requested for the data). A surgical computing system may obtain the surgical procedure data from surgical systems. The surgical computing system may annotate the surgical procedure data with surgical context data. The surgical computing system may determine a data need associated with a subsequent target system task associated with a target system. The surgical computing system may determine the target system, for example, based on the annotated surgical procedure data. The surgical computing system may generate a data package associated with the data needs, which may comprise a portion of the annotated surgical procedure data. The surgical computing system may send the data package to the target system.
PURPOSE:To obtain antigen-specific B cell useful for the mass production of antibody by cell fusion technique, economically, by culturing a variety of heterogeneous sensitized B cell in the presence of an antigen-specific proliferation factor derived from T cell. CONSTITUTION:An antigen-specific B cell can be prepared by culturing sensitized B cell in the presence of an antigen-specific proliferation factor originated from T cell. The proliferation factor can be collected from the supernatant liquid obtained e.g. by exposing a mouse to radiation, administering the mouse with about 2X10<8>-2X10<9> thymic cells of the same kind and the usual immunizing amount of antigen, extirpating the splenic cells after 4-10 days, and centrifuging the suspension of the cells. The collected factor can be purified by the affinity chromatography using a complex of a specific antigen and a carrier as an adsorbent. Since antigen-specific B cells can be prepared from the B cells sensitized with crude antigen, the process has an advantage that the crude antigen can be used as a raw material.
Enoxaparin sodium injection, USP is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. The pH of the injection is 5.5 to 7.5.

Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. Its structure is characterized by a 2-O-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine at the reducing end of the chain. About 20% (ranging between 15% and 25%) of the enoxaparin structure contains a 1,6 anhydro derivative on the reducing end of the polysaccharide chain. The drug substance is the sodium salt. The average molecular weight is about 4500 daltons. The molecular weight distribution is:

STRUCTURAL FORMULA

Enoxaparin Sodium Injection, USP 100 mg/mL Concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

Enoxaparin Sodium Injection, USP 150 mg/mL Concentration contains 15 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.

The enoxaparin sodium injection, USP prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection. [see Dosage and Administration (2) and How Supplied/Storage and Handling (16)].
Foot drop is a condition characterized by the inability to lift the foot upwards towards the shin bone. This condition may affect a proportion of critically ill patients, impacting on their recovery after the acute phase of the illness. The occurrence of foot drop in critical care patients may result from various underlying causes, including neurological injuries, muscular dysfunction, nerve compression, or vascular compromise. Understanding the etiology and assessing the severity of foot drop in these patients is essential for implementing appropriate management strategies and ensuring better patient outcomes. In this comprehensive review, we explore the complexities of foot drop in critically ill patients. We search for the potential risk factors that contribute to its development during critical illness, the impact it has on patients' functional abilities, and the various diagnostic techniques adopted to evaluate its severity. Additionally, we discuss current treatment approaches, rehabilitation strategies, and preventive measures to mitigate the adverse effects of foot drop in the critical care setting. Furthermore, we explore the roles of critical care physical therapists, neurologists, and other healthcare professionals in the comprehensive care of patients with foot drop syndrome and in such highlighting the importance of a multidisciplinary approach.
The invention relates to the technical field of eye care products, in particular to a freeze-dried powder preparation for preventing and improving and nursing xerophthalmia, which consists of freeze-dried powder, solution and a composite preparation. The lyophilized powder contains vitamins, pyrimidine carboxylic acid and active peptide as effective components, wherein the vitamins include at least two of riboflavin, pyridoxine, and cyanocobalamin; pyrimidine carboxylic acids are preferably tetrahydro-methyl-pyrimidine carboxylic acids; the active peptide comprises one or more of oligopeptide-1, oligopeptide-2, oligopeptide-3 and oligopeptide-5, preferably oligopeptide-1 and oligopeptide-5. The solvent is composed of taurine, rubusine, dipotassium glycyrrhizinate, lysozyme and water as effective components. The compound preparation is prepared by fusing a solvent and freeze-dried powder. The invention also provides a preparation method of the freeze-dried powder preparation for preventing and improving the dry eye disease. The freeze-dried powder preparation has no stimulation and toxic or side effect, can be used for eyes to achieve the effects of moisturizing, soothing and activating, enhancing immunity and has good effects of preventing and improving eye dry eye symptoms.
Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.